Eton Pharmaceuticals Inc
Research Eton Pharmaceuticals Inc (ETON) on Bullrun: market cap USD 1.01B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerETON
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 1.01B
- Financial periodFY2025
- RevenueUSD 79.95M
- Revenue growth104.9%
- Net income-USD 4.60M
- Free cash flowUSD 10.19M
- Gross margin53.5%
Valuation Snapshot
latest market cap is USD 1.01B.
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Frequently asked questions
What is Eton Pharmaceuticals Inc's market cap?
Eton Pharmaceuticals Inc's market capitalization is USD 1.01B.
What does Eton Pharmaceuticals Inc do?
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency;